Abeona files Wainwright investor deck, but offers no new operating data

Abeona is a commercial-stage cell-and-gene-therapy company shifting from ZEVASKYN launch execution toward broader pipeline development, including the early-stage ABO-701 solid-tumor program. Its latest reported operating story was already public: ZEVASKYN revenue and treatment volume were growing, while cash remained available to fund the rollout and pipeline work.

This filing is presentation logistics, not a business event. Abeona says it is furnishing an updated investor presentation for its September 15, 2026 H.C. Wainwright conference. 〔0〕 The conference itself was announced on September 2, so the existence of the presentation was already known; the supplied filing does not include the Exhibit 99.1 slides or disclose new milestones, financials, guidance, regulatory outcomes, or financing terms.

Bottom line: This filing does not change Abeona’s operating story. Any significance depends on details in the missing presentation or on what management says at the conference, not on the 8-K itself.